Table 1.

Clinical trials with empagliflozin

Study	Treatment	Duration	Drug/placebo	HbA1c (%)	HbA1c <7% at the end of treatment (%)	FPG (mmol/L)	Body weight (kg)	Systolic blood pressure	Diastolic blood pressure
Heise et al17	1. Empagliflozin 10 mg, 25 mg, 100 mg 2. Placebo	28 days	52/16	−0.4#,§		−2.4**,#,§	−1.5#,§
Heise et al18	1. Empagliflozin 2.5 mg, 10 mg, 25 mg, 100 mg 2. Placebo	8 days	36/12			−2.2*,#,§
Kadowaki et al22	1. Empagliflozin 5 mg, 10 mg, 25 mg, 50 mg 2. Placebo	12 weeks	438/109	−0.9#,¶,**	35#	−2#,¶,**	−2.2#,¶,**	−4#,¶,*	−1.6#,¶,*
Ferrannini et al24	1. Empagliflozin 5 mg, 10 mg, 25 mg 2. Placebo 3. Metformin	12 weeks	324/82	−0.6***,#,§	45*,#	−1.7***,#,§	−2***,#,§
Roden et al25	1. Empagliflozin 10 mg, 25 mg 2. Sitagliptin 100 mg 3. Empagliflozin 25 mg (open label)	24 weeks	448/228	−0.9#,¶,***	44#	−2***,#,¶	−2***,#,¶	−3*,#,¶	−1.5*,#,¶
Nishimura et al26	1. Empagliflozin 10 mg, 25 mg 2. Placebo	4 weeks	39/21	−0.6**,#,§		−2.2#,§	−2#,§	−6#,§	−5#,§
Haring et al27	1. Empagliflozin 10 mg, 25 mg 2. Placebo 3. Metformin	24 weeks	430/207	−0.8**,#,§	39#	−1.2**,#,§	−2**,#,§	−5**,#,§	−1.6*,#,§
Rosenstock et al11	1. Empagliflozin 1 mg, 5 mg, 10 mg, 25 mg, 50 mg 2. Placebo 3. Sitagliptin 100 mg 4. Metformin	12 weeks	353/71	−0.6**,#,§	37#,§	−1.6***,#,§	−2.9***,#,§	−3§	−2§
Kovacs et al6	1. Empagliflozin 10 mg, 25 mg 2. Placebo 3. Pioglitazone 4. +/− Metformin	24 weeks	333/165	−0.7**,#,§	48#	−1.2**,#,§	−1.6**,#,§	−4**,#,§	−2.2**,#,§
Rosenstock et al31	1. Empagliflozin 10 mg, 25 mg 2. Placebo 3. Insulin	52 weeks	275/188	−0.6**,#,§		−2.5**,#,§	−2**,#,§	−4*,#,§

Notes:

^*P<0.05 compared to the placebo.

^**P<0.001 compared to the placebo.

^***P<0.0001 compared to the placebo.

^#Maximum effect.

^§Changes from baseline to the end of treatment.

^¶Differences vs placebo in changes from baseline.

Abbreviations: FPG, fasting plasma glucose; HbA_1c, glycosylated hemoglobin.